Endoscopy Fluid Management Systems Market estimated to increase to 7.2% CAGR throughout the forecast period 2021-2028

Laparoscopy Suction Irrigation Pumps are likely to remain the top selling product type, whereas developing economies are projected to demonstrate impressive revenue growth in coming years.

Providing a brief overview of the FDA regulations for Class II medical devices such as endoscopes, a new study presented by Future Market Insights offers an exhaustive assessment of the global endoscopy fluid management systems landscape for a 10-year projection period, 2018-2028.

According to the FMI study, as the Tier 1 players continue to contribute over 70% share of the market revenue, the global endoscopy fluid management systems landscape remains a highly consolidated space.

The report covers extensive profiling of the top four performers including a few of the biggest industry names such as Stryker Corporation and Olympus Corporation. However, research indicates that even local players have strong penetration in regional markets.

To remain ‘ahead’ of your competitors, request for a sample

Top 3 Insights from Key Players Analysis

While a majority of companies are focusing on new product launches, strategic mergers and acquisitions are likely to emerge the most profitable developmental decisions in the near future. Most of these strategic moves will be primarily directed to address the high price point pressure associated with endoscopy fluid management systems that often affects revenue growth in developing economies. Major hospital networks in developed regional markets are witnessing M&A between hospitals, which is likely to shape costing of medical devices such as endoscopy fluid management systems – eventually slashing down the profitability margins of manufacturers. “Constantly increasing chronic disease instances, coupled with immense technological advances in the field of endoscopy, is prominently driving the US$ 342 Million market for endoscopy fluid management systems (or irrigation pumps) in recent years,” says a senior research analyst at the company.

Prominent Players:

Karl Storz GmbH & Co KG
Olympus Corporation
Richard Wolf GmbH
Smith & Nephew
Stryker Corporation
DePuy Synthes (Johnson & Johnson Services Inc.)
Cantel Medical Corporation
Medtronics Plc.
B. Braun Medical Inc. and Hologic Inc

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-4358

Top 5 Insights from Segmental Analysis

With maximum use in laparoscopic procedures, endoscopy fluid management systems continue to register maximum revenue generation through sales of laparoscopy suction irrigation pumps, followed by laparoscopy fluid management systems.

Based on the modality of endoscopy fluid management systems, the Benchtop holds a substantial market value share.

Hospitals register the highest consumption of endoscopy fluid management systems.

Owing to a massive number of cancer survivors in the US, North America’s market for endoscopy fluid management systems is currently accounting for the largest revenue share in the global landscape, followed by Asia Pacific and Europe.

MEA and Latin America are likely to represent a significant incremental opportunity, according to FMI study.

Healthy Year over Year Revenue Growth Projected for Asia Pacific

APAC has become the hotspot for leading medical device companies, which is further intensified by dramatically growing medical tourism sector. Across APAC, Japan is likely to account for substantial revenue generation, enabling the regional market secure second spot in the global endoscopy fluid management systems landscape. FMI projects over 7% year on year revenue growth in 2020 and beyond, for this regional market.

Government Regulations Favor Market Growth in Latin America

Latin American market for endoscopy fluid management systems is thriving at a promising pace owing to favorable government initiatives regarding endoscopic procedures and medical device marketing. Noteworthy demand for laparoscopy suction irrigation pumps within the region is identified to be responsible for the rapid revenue growth of endoscopy fluid management systems marketplace across Latin America.

Egypt’s End Users Drive Market Growth in MEA

The market for endoscopy fluid management systems in MEA is prominently driven by the improving regulatory landscape related to the marketing of medical devices, pushed further by impressive sales of laparoscopy suction irrigation pump based endoscopy fluid management systems. FMI spots higher market attractiveness in Egypt owing to the presence of a large number of end users. However, poor operational environment still remains a major growth barrier for the region.

For in-depth competitive analysis Buy Now – https://www.futuremarketinsights.com/checkout/4358

Segmentation

The report offers a comprehensive taxonomy of the endoscopy fluid management systems market based on product type, end user, modality and region. Endoscopy fluid management systems are used for various types of endoscopic surgeries such as hysteroscopy and laparoscopy.. End-user segments in the endoscopy fluid management systems market include hospitals, ambulatory surgical centers and other end users, such as specialty clinics & diagnostic centers.

From a regional perspective, the endoscopy fluid management systems market has been analyzed across North America, Latin America, Europe, Asia Pacific and Middle East & Africa.

Psoriatic Arthritis (PsA) Treatment Market is expected to grow at an approximate CAGR of 7.2% over 2021-2028

Nearly 70% of the psoriasis patient population is prone to psoriatic arthritis, and up to 20% of arthritis patients are susceptible to acquire psoriasis, according to the recent findings of the Arthritis Foundation.

The rate of increasing burden of psoriasis and psoriatic arthritis on healthcare industry has been boosting clinical research in the field of psoriatic arthritis, in recent years.

Sustained adoption of conventional disease modifying anti-rheumatic drugs (DMARDs), especially in cost sensitive regions, is projected to push the demand for psoriatic arthritis treatment in coming years.

Psoriatic Arthritis (PsA) Treatment Market – Key Research Findings

Global Psoriatic Arthritis (PsA) treatment market size in 2018 – nearly US$ 7,800 Mn.

The Psoriatic Arthritis (PsA) treatment market is expected to grow at an approximate CAGR of 7.2% over 2018-2028.

North America and Europe are expected to remain the largest regional markets for Psoriatic Arthritis (PsA) treatment

North America and Europe are among the prominent regions in the Psoriatic Arthritis (PsA) treatment market owing to the increasing adoption of biologics and biosimilars, along with the growing adoption of combination treatment for psoriatic arthritis.

To remain ‘ahead’ of your competitors, request for a sample

Prominent Players:

Pfizer Inc.
Bristol-Myers Squibb Company
Johnson & Johnson Services
Inc.
AbbVie Inc.
Amgen Inc.
Novartis AG
AstraZeneca Plc UCB S.A.
Eli Lilly & Co
and Celgene Corporation

Role of Strong Product Pipeline & Mounting Clinical Research Investments

Over 20 drugs for psoriasis and psoriatic arthritis are currently in the phase II of pipeline, whereas more than 28 are in phase III of clinical trial, as indicated by the National Psoriasis Foundation. However, around 24 drugs have already received FDA approval for inclusion in the treatment for psoriasis and psoriatic arthritis.

While such a strong product pipeline continues to drive the demand for psoriasis and psoriatic arthritis treatment, a new research points to the shifting focus of several drug manufacturers to competitive pricing strategies, in an effort to attain widespread acceptance in coming years. Recently, Future Market Insights released a new intelligence based on the analysis of global psoriatic arthritis treatment market. The study forecasts a robust over-7% yearly growth for the market in 2019.

Industry Behemoths Cover More than 55% Market Value Share

In a fairly consolidated global landscape of psoriatic arthritis treatment market, more than 55% share of the total revenue is accounted by industry giants such as Novartis AG and AbbVie Inc. that include biologics in their core portfolio. While market leaders are maintaining focus on FDA approvals and clinical trials, research also points to the increasing importance of diverse pricing strategies.

Moreover, prominent players in psoriatic arthritis treatment market are likely to augment investments in R&D of biosimilars, biologics, and TNF (tumor necrosis factor) inhibitors to target regional markets. A number of leading drug manufacturers are also maintaining sizable investments in DMARDs that are scheduled for market entry in next few years. This is perceived as a strong factor improving growth prospects of psoriatic arthritis treatment market, according to the report.

Besides all these, strategic acquisitions, partnerships, and collaborations will remain the preferred expansion strategies adopted by a majority of prominent operators in psoriatic arthritis treatment landscape,” says a senior research analyst at the company.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-2718

Demand for Biologics & DMARDs Gaining Momentum

Research-driven understanding of the pathophysiology of psoriatic arthritis is fueling the introduction of innovative therapies in psoriatic arthritis treatment market, triggering innovations among the market participants – thereby supporting the growth of psoriatic arthritis treatment market. Targeted biological therapy has been demonstrating a decent success rate in terms of inducing temporary pain relief resultant of psoriatic arthritis, and thus continues to represent an attractive position in the psoriatic arthritis treatment market.

The report says that the demand for biologics accounts for more than 55% share of the global market revenue, whereas DMARDs demand makes up for more than 3/4th of the total market value. Although a majority of psoriatic arthritis patients opt for injectable as a preferred route of administration of psoriatic arthritis treatment, increasing introduction of innovative oral drugs is uplifting the popularity of orally administered psoriatic arthritis treatment.

Development of novel oral treatments for psoriatic arthritis is likely to favor the growth of North America’s market. Growing availability of combination therapies and relatively economical biosimilar antibody therapeutics are identified to be the primary boosters for the growth of Europe’s market. Collectively, North America and Europe account for over 60% share in the global value of psoriatic arthritis treatment market. The report indicates that the psoriatic arthritis market in Asia Pacific is likely to display high growth potential in the course of next few years.

PSORIATIC ARTHRITIS (PSA) TREATMENT MARKET TAXONOMY

The global psoriatic arthritis (PsA) treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.

By Product

Non-steroidal anti-inflammatory drugs

Disease modifying Anti-rheumatic drugs

Corticosteroids

Antimalarial

Methotrexate

Others

Biologics

TNF Inhibitors

Interleukin inhibitors

By Route of Administration

Oral

Injectable

By Distribution Channel

Hospital pharmacies,

Retail pharmacies,

Mail order pharmacies

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-2718

Region

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East & Africa

Donor Egg IVF (In-Vitro Fertilization) Market Advanced Research & Growth Opportunities In Global Industry By 2028 Edited By Leading Research Firm

Adoption of donor egg IVF treatment accounted for the approximate revenue of US$ 2 billion in 2018, which are likely to witness a healthy spike by 6.7% in 2019. Future Market Insights (FMI) recently presented a research study on the global donor egg IVF market, according to which a majority of overall adoption is registered at fertility clinics and IVF centers.

A Majority of Patients Seek Donor Egg IVF Treatment at Fertility Clinics & IVF Centers

Donor egg IVF is a procedure in which technological and pharmacological manipulation is used to help and promote pregnancy, the procedure has gained significant ground globally, in recent years. Donor egg IVF has rapidly become one of the most sought after fertility treatment alternatives among the infertile population.

The study opines that fresh donor egg cycle has been preferred over frozen donor egg cycle, attributed to the associated high rates of pregnancy and successful births. Currently, nearly 70% of donor egg IVF treatment adoption is recorded at IVF centers and fertility clinics, and more than 70% of the times, the procedure is conducted by using fresh donor egg cycle.

In the fresh donor egg cycle, eggs are retrieved, following which they are fertilized immediately and directly transferred to the recipient’s womb (uterus). The birth rate and pregnancy rate by using fresh donor egg cycle are estimated to be more than 36% and 55%, respectively. On the flipside, the birth rate and pregnancy rate by using a frozen donor egg cycle are just about 24% and 39%, respectively. According to the report, enhanced pregnancy and birth rates will continue to advocate preference for fresh donor egg IVF over frozen.

To remain ‘ahead’ of your competitors, request for a sample

The Rising Burden of Infertility Pushing Scope of Egg Donor IVF Adoption

As concluded by FMI’s analysis, with an increasing number of couples postponing first pregnancy that generally leads to higher prevalence of age-related infertility issues, it is highly likely that procedures such as in-vitro fertilization (IVF) and a step ahead, donor egg IVF, will continue to witness robust demand in years to come.

Research has proven that the number of women with ovaries that have untimely ceased to function has been on a considerable rise over the recent past, and thus, donor egg remains the only chance for them to conceive and lead a successful pregnancy period. The increasing infertility burden is complemented by a strong increase in the number of female egg donors, which has been cited as another important factor pushing prospects of donor egg IVF market.

Europe’s donor egg IVF market is expected to witness strong growth in forthcoming years, followed by North America, as a result of high inbound of infertile population opting for fertility treatment, across the region. Moreover, the expensive costs of donor egg IVF treatment and favorable government initiatives and reimbursements on the same are accounting for prominence of these regions in global donor egg IVF industry. The report also indicates that donor egg IVF market in Asia Pacific will demonstrate high growth potential through the coming years, as a considerably large patient pool is seeking fertility solutions.

A majority of European countries offer good service at a reasonable budget for donor egg IVF procedures and some countries, such as Brazil and Australia, reimburse 50% of the treatment cost for unsuccessful donor egg IVF procedures, or reimburse other expenses such as accommodation or out-of-pocket costs for egg donors.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-2499

DONOR EGG IVF (IN-VITRO FERTILIZATION) MARKET TAXONOMY
The global donor egg IVF market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.

By Cycle Type

Fresh Donor Egg Cycle
Frozen Donor Egg Cycle

By End User

Direct / Patient
Hospitals
Fertility Clinics & IVF Centres

By Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-2499

Oral Controlled Release Drug Delivery Technology Market To Register An Impressive Expansion At 7.2% CAGR And Estimated To Reach Nearly US$ 50,000 Million By 2027-End

Future Market Insights (FMI), in its report, projects the global oral controlled release drug delivery technology market to register an impressive expansion at 7.2% CAGR during the forecast period 2017 to 2027. The market will surpass revenues worth US$ 20,000 Mn in 2017, and is further estimated to reach nearly US$ 50,000 Mn by 2027-end.

Oral Solid Dosage Manufacturers in North America Enabled to Achieve Significant Bioavailability

FMI’s report estimates North America to remain the largest market for oral controlled release drug delivery technology, with sales estimated to reach nearly US$ 20,000 Mn by 2027-end. Being preferred route of drug administration by physicians, demand for oral controlled release drug delivery technology has been witnessing a surge by end-users in North America. In addition, recent advancements in drug delivery have enabled oral solid dosage manufacturers in North America to achieve significant bioavailability through adoption of novel drug delivery platforms. This is further expected to drive demand for oral controlled release drug delivery technology in the region.

However, increasing research activities related to biologic molecules, and their dominance in treating oncology conditions, coupled with government investments in these research activities are expected to impede the market growth in North America. In addition, formulation challenges such as juncture of market expectations for once-daily dosing, and growth of controlled release tablets which impart abuse resistance, incurred in oral controlled release drug delivery technology are expected to further curb growth of the market in this region.

To remain ‘ahead’ of your competitors, request for a sample

New Chemical Entities Resulting from High Throughput Screening to Drive Market Growth in Western Europe

Western Europe will register the fastest expansion in the global oral controlled release drug delivery technology market. This growth is primarily attributed to a slew of new chemical entities resulting from high throughput screening, which have low solubility and bioavailability. This has further led manufacturers in this region to invest in drug delivery methods with better clinical outcome. Owing to cost-sensitiveness in Western European countries, technologies enhancing bioavailability will remain preferred drug delivery system. These factors are expected to drive growth of the market in this region.

However, most of the pharmaceutical companies in Western Europe have complex supply chain, which is either under-utilised or inefficient. Complexity of supply chain is attributed to low flexibility and cost-effectiveness. In addition, shortening of effective patent life along with patent cliffs is a major challenge for oral solid dosage forms in this region. Factors such as these are estimated to hinder growth of the market in Western Europe.

Dissolution-Controlled Release System to Remain Sought-After among Drug Release Technologies in the Market

By drug release technology, dissolution-controlled release system will remain sought-after in the market, followed by diffusion-controlled release system. Majority of generic formulations available are in tablet dosage form and follow dissolution-controlled release mechanism. Revenues from sales of dissolution-controlled release system will surpass US$ 10,000 Mn in 2017. Demand for hydrodynamically-balanced drug delivery system will remain sluggish in the market.

Solid dosage forms of oral controlled release drug delivery technology are expected to remain dominant in the market, expanding at a high single-digit CAGR through 2027. Sales of semisolid/liquid/suspensions dosage form segment will register a comparatively lower CAGR than that of solid dosage forms in the market through 2027.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-4400

Key market players identified in FMI’s report include

AstraZeneca Plc.,

Bristol-Myers Squibb Company,

Sun Pharmaceuticals Industries Ltd,

Abbott Laboratories,

Merck & Co. Inc.,

Novartis AG,

Pfizer Inc.,

Mylan N.V.,

Sanofi,

F. Hoffman-La-Roche Ltd.,

Johnson & Johnson Services, Inc.,

Vectura Group plc.,

GlaxoSmithKline plc.

Market Taxonomy

By Region

North America

Latin America

Western Europe

Eastern Europe

APEJ

Japan

MEA

By Drug Release System

Diffusion Controlled Release System

Dissolution Controlled Release System

Osmotically Controlled Release System

Dissolution & Diffusion Controlled Release System

Ion Exchange Resins Controlled Release

Hydro-dynamically Balanced Drug Delivery System

Others

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-4400

By Dosage Form

  • Solid Dosage Forms
  • Semisolid
  • Liquid/Suspension

Anti-Microbial/Anti-Fungal Tests Market Is Expected To Witness A Robust CAGR Of 6% From 2021 To 2027

Microbial and fungal infections are a major cause of death globally and can even cause potential epidemics, creating a huge economic burden on countries, especially developing ones. To nip the spread of such infections in the bud, prevention is a far better solution than cure – accomplished by isolating infected cases and carrying out primary screening tests. Future Market Insights in its report titled ‘Anti-microbial/Anti-fungal Tests Market: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027’ has comprehensively analysed the global anti-microbial/ anti-fungal tests market for a decade. The anti-microbial/ anti-fungal tests market is expected to witness a robust CAGR of 6% from 2017 to 2027.

Region – Robust Healthcare Infrastructure in North America Enables Rapid Anti-Microbial/ Anti-Fungal Testing

North America has the largest regional contribution and is predicted to account for approx. a third of the anti-microbial/ anti-fungal tests market at the end of the forecast period. The North America anti-microbial/ anti-fungal tests market should cross a billion dollars by 2027 – the only region to do so. Most physicians on the continent typically prescribe diagnostics tests before starting any sort of treatment, fuelling demand for anti-microbial/ anti-fungal test kits. Furthermore, there is immense awareness of the side-effects of certain drugs and patients often prefer to get completely diagnosed before seeking treatment.

Test Type – Molecular Based Tests Critical in Anti-Microbial/ Anti-Fungal Tests Market

Molecular based tests dominated the global anti-microbial/ anti-fungal tests market by test type in 2017 and are likely to retain this commanding position for the foreseeable future. Molecular based tests have a market attractiveness index of 2.6 – considerably higher than all other test types in the anti-microbial/ anti-fungal tests market. Within the molecular based tests segment, companies would be advised to focus their attention on the PCR Test sub-segment as it is roughly thrice the size of DNA microarray tests in terms of value. The PCR test segment is further poised to record a CAGR of 6.4% for the decadal study.

To remain ‘ahead’ of your competitors, request for a sample

Infection Type – Target Antimicrobial Resistance and Microbial Infection Segments in Anti-Microbial/ Anti-Fungal Tests Market

The antimicrobial and microbial resistance segments are the ones to look out for as they comprise almost 3/4th of the global anti-microbial/ anti-fungal tests market between them. The multi-drug-resistant mycobacterium tuberculosis sub-segment is the largest in the antimicrobial resistance segment and should grow at a high rate as well. Along with multi-drug-resistant mycobacterium tuberculosis, the microbial infection segment holds great potential in the anti-microbial/ anti-fungal tests market as it is on track to push past a value of US$ 1 billion by end 2027.

End User – Hospitals and Reference Labs Demand Antimicrobial/ Antifungal Testing Kits

Hospitals and reference labs are the largest end users in the anti-microbial/ anti-fungal tests market by a substantial margin. It has been observed that the global per-capita healthcare spending has doubled because of rising awareness of myriad treatment options and diagnostic tools for detecting and curing various diseases. Reference labs are predicted to grow faster than hospitals in the anti-microbial/ anti-fungal tests market.

Competition Dashboard in the Anti-Microbial/ Anti-Fungal Tests Market

The companies profiled in the report are

  • Abbott Laboratories
  • bioMérieux SA
  • Bio-Rad Laboratories
  • Bruker Corporation
  • Danaher Corporation
  • Erba Mannheim
  • F. Hoffmann-La Roche AG
  • Luminex Corporation
  • Meridian Bioscience
  • Norgen Biotek Corp.
  • Omega Diagnostics Group Plc.
  • Qiagen N.V.
  • Quidel Corporation
  • Thermo Fisher Scientific Inc

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-5566

Takeaways

The prevalence and incidence rate of infectious diseases such as diarrhoea and malaria is at an all-time high in Asia and Africa. Governmental and non-governmental organizations such as the WHO are seeking to reduce prevalence rates by early diagnosis through antimicrobial and antifungal kits. In addition to this, government tenders and partnerships with manufacturers is anticipated to provide a steady revenue stream for the latter, growing the  anti-microbial/ anti-fungal tests market as a whole.

Anti-Microbial/Anti-Fungal Tests Market Taxonomy

Test Types

  • Molecular Based Tests
    • PCR Test
    • DNA Microarray
  • Phenotypic Resistance Tests
  • Complex Test Panels
  • Mass Spectrometry
  • Rapid Diagnostic Tests
    • E-Test Antibiotic/Antifungal Strips
    • Biosensor Platforms

End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Community Health Centers
  • Reference Laboratories

Type

  • Antimicrobial Resistance
    • Methicillin-Resistant Staphylococcus Aureus
    • Vancomycin-Resistant Enterococcus
    • Multi-Drug-Resistant Mycobacterium tuberculosis
    • Carbapenem-Resistant Enterobacteriaceae gut bacteria
  • Microbial Infection
  • Antifungal Resistance
    • Candida infections
    • Aspergillus infection
    • Fusariosis
    • Others
  • Fungal Infection

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-5566

Region

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific excluding Japan
  • Japan
  • Middle East and Africa

External Fixators Market Is Estimated To Expand At A High CAGR Of 8.5% During The Report Period (2018–2028) With Valuation Surpassing The US$ 3 Billion

The external fixators market is projected to continue its steady growth on account of the widespread prevalence of osteoporosis coupled with rising incidences of accidental fractures. The external fixators market is estimated to expand at a high CAGR of 8.5% during the report period (2018–2028), with market valuation surpassing the US$ 3 billion mark by 2028 end.  According to the FMI external fixators market report, technologically and innovative advancements are anticipated to further firm-up the adoption of external fixators.

In recent years, orthopedic treatments have witnessed a paradigm shift from the conventional highly-invasive to minimally-invasive procedures as the latter promises early return-to-motion with negligible infection risks. The computer-aided external fixators have been built upon the strengths of conventional external fixators by boosting the device convenience and versatility in complex cases. The FMI report on external fixators market opines that computer-aided external fixators could witness increased adoption, expanding considerably in the forthcoming years.

“Alternative orthopedic disorders’ treatment options, including bone glue designed for joint replacement, could hinder global external fixators market growth considerably. Several external fixators’ manufacturers are prioritizing novel technologically-advanced product development, but stringent rules and regulations in tandem with the lengthy approval procedures are making market-penetration challenging for new devices. This is prompting patients to opt for external fixators’ alternative. Additionally, widespread prevalence of surgical-site infections in the case of orthopedic trauma operations over surgical specialties, is another vital factor ebbing progress of external fixators market,” says a lead analyst at Future Market Insights.

To remain ‘ahead’ of your competitors, request for a sample

Amid the numerous challenges in external fixators market, manufacturers are increasingly focusing on novel product launches, mergers, expansion, acquisitions, and deals, while also implementing forward growth strategies to proliferate the sales of their offerings in broader geographies. As per FMI external fixators market report, manufacturers are also prioritizing New Product Development (NPD) strategies to reinforce their footprint in Asia Pacific region, which is the hotbed of opportunities in external fixators market. External fixators’ manufacturers are leveraging 3D printing to build patient-focused devices with complex internal structures. Owing to 3D printings’ myriad benefits in the orthopedic industry, such an inclusion is expected to fuel sales of external fixators.

As per the FMI report on external fixators market, moguls in the external fixators market, including the leading four players Stryker Corporation, Smith & Nephew, DePuy Synthesis, and Zimmer, accumulatively hold nearly half the external fixators market share. The external fixators market represents a highly consolidated landscape, with most of the growth opportunities emerging in North America. However, the report comprehends that a fortified global external fixators market will result in high-priced devices.

Geographically, North America is projected to hold roughly 35% share of external fixators market, however, New Zealand and Australia are anticipated to present most lucrative growth opportunities in Asia Pacific market, followed by Latin America and Middle-East and Africa. The external fixators’ manufacturers are targeting emerging markets owing to increased procedural awareness, in tandem with sophisticated diagnostics capabilities in these regions, propelled by proliferating demand for affordable and quality healthcare.

Key players operating in external fixators market include:

  • Ortho-SUV Ltd.
  • ConMed
  • Zimmer Biomet Holdings Inc.
  • OsteoMed
  • DePuy Synthes (Johnson & Johnson Services Inc.)
  • Stryker Corporation
  • Medtronic Kanghui Orthopedics
  • Vilex
  • DJO Global Inc.
  • Response Ortho LLC
  • Wright Medical Group N.V.
  • Bioventus
  • Orthofix International N.V.
  • Acumed
  • Integra LifeSciences Corporation
  • Smith & Nephew plc.

 

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-8971

 

Key Segments

By Product Type

 

  • Manual Fixators
  • Computer Aided External Fixator

 

By Application

 

  • Orthopedic Deformities
  • Fracture Fixation
  • Infected Fracture or Non-Unions
  • Limb Correction
  • Others

 

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-8971

 

By End User

 

  • Hospitals
  • Ambulatory Surgical Centers
  • Orthopedic and Trauma Centers

 

By Country

 

  • U.S.
  • Canada

 

Generic Oncology Drugs Market Is Poised To Surpass A Striking CAGR Of 6% Through 2028

Generic oncology drugs, being able to detect and treat tumors, are utilized extensively in the healthcare industry for treating cancer. Notable enhancements in the technology with the blend of information is expected to accelerate the pace of growth for the generic oncology drugs market and the cost pertaining to the treatment of cancer. Advanced technologies such as real world data, mobile apps, and artificial intelligence have successfully been able to achieve a high engagement rate of the patients, which has resulted in increasing awareness of the cancer treatment among the patients.

A significant increase has been noted in the spending capacity for the development of cancer. More than one-third of the trials proposed by the manufacturers are aimed at offering personalized cancer treatments, which further propels the demand for generic oncology drugs. A host of these factors have contributed massively to the expansion of the generic oncology drugs market at the global level.

According to a report, the global generic oncology drugs market is poised to surpass a striking CAGR of 6% through 2028. Increasing inclination of individuals towards smoking and tobacco consumption is the chief cause of cancer. Secondary factors such as sedentary lifestyle, genetic causes, viral infections, carcinogens, and high consumption of junk food make the human body susceptible to cancer. Growing concerns of a high number of deaths occurring on the back of cancer have provoked the government authorities to take effective steps for preventing cancer.

Increasing incidences of cancer have been detected, ascending from the proclivity for cigarettes and tobacco among individuals. The number of cancer-infected patients is stimulated by viral infections, carcinogens, lack of physical activities, genetic causes, age, and unhealthy eating habits. Recent developments in the healthcare sector have broadened the scope of therapies for the treatment of cancer by leveraging oncology.

To remain ‘ahead’ of your competitors, request for a sample

Notable Developments in the Generic Oncology Drugs Market

Improvement in cancer treatment drugs and therapies have been one of the most underlying aims of the pharmaceuticals and medical organizations operating at the global level. Consequently, generic oncology drugs have been utilized for innovating novel therapies and increasing the survival rates of patients.

Blood Cancer Immensely Contributes to the Growth of the Generic Oncology Drugs Market

Amongst the various types of cancer such as skin cancer, bladder cancer, bone cancer, eye cancer, gastrointestinal cancer, gynecological cancer, lung cancer, endocrine cancer, and blood cancer is accounted for generating the largest share for the generic oncology drugs market. Patients diagnosed with blood cancer seek complete treatment to this chronic disease, as a result of which excessive demand for generic oncology drugs is created. In addition to this, the high cost of the therapies and generic oncology drugs play a crucial role in the growing size of the generic oncology drugs market.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-8961

Recent Developments to Drive the Growth of the Generic Oncology Drugs Market

The key players involved in transforming the landscape of the generic oncology drugs market include

  • Bayer Healthcare AG
  • Amgen
  • Teva Pharmaceutical Industries
  • Pfizer
  • Boehringer Ingelheim GmbH
  • AstraZeneca
  • Hoffmann-La Roche Ltd.
  • Eli Lily and Company
  • ARIAD Pharmaceuticals Inc.
  • GlaxoSmithKline
  • CELGENE Corporation
  • Novartis AG
  • Johnson and Johnson
  • AbbVie Inc.
  • Merck & Co.
  • Sanofi

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-8961

Out of these leading players, CELGENE, Novartis, and Roche have been procuring a considerable share in the generic oncology drugs market with a rich product portfolio and pipeline products aimed at treating cancer effectively.

Novartis AG applied smart strategies for channel integration like eCommerce with mobile application to fuel the sales at the retail stores. In addition to this, the company achieved a CE mark for its gene modifying therapy used for the treatment of blood cancer.

Pfizer Inc. has been focusing on the over 39 therapies, in order to fortify its product portfolio. In the year 2017, Glasdegib of Pfizer received the priority review from the U.S. FDA to treat myeloid leukemia. Post this, XTANDI of Pfizer as well received the FDA approval.

Many similar key development shaping the landscape of the existing generic oncology drugs market have been incorporated in the report.

Antibiotic Susceptibility Testing Market Is Anticipated To Expand At A CAGR Of 5.6% Over The Forecast Period 2021–2028

Growing use of antibiotics in treating even the most common health conditions remains a strong factor boosting demand for antibiotic susceptibility testing (AST). Increasing government funds for microbial and antibiotic susceptibility testing research and consistently improving outcome of PPPs in terms of enhanced screening and evaluation of antibiotics are playing a pivotal role in strengthening the performance of antibiotic susceptibility testing market. CDC’s ‘AMR Challenge’ involving bioMérieux is a recently announced as objective to accelerate research efforts in the field of microbial resistance.

A recently published research intelligence on the global antibiotic susceptibility testing market by Future Market Insights tracks the top five influencers pushing demand and revenue growth of the market at a global level.

  • Infectious diseases, prevailing at a high pace
  • Increasing rate and tenure of hospitalization
  • Growing significance of early diagnostics
  • Soaring research interests in microbial susceptibility testing
  • Improving funding scenario for research, driven by governments & private bodies

Towards 2019, global revenue through total installed base of antibiotic susceptibility testing systems is likely to see 6.4% yearly growth over that achieved in 2018.

To remain ‘ahead’ of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-8574

Prominent Players:

  • BD
  • Danaher
  • Thermo Fischer Scientific
  • Bio-Rad Laboratories
  • Creative Diagnostics
  • Accelerate Diagnostics
  • Alifax
  • Liofilchem srl
  • bioMérieux SA
  • Merck KgaA

Entry of Technologically Advanced AST Systems to Favor Market Growth

As indicated by research, the sales of antibiotic susceptibility testing equipment will witness healthy growth owing to increasing demand for specific susceptibility testing systems to define the scope of targeted therapy. Targeting key pathogens is imperative to design a highly specific plan of treatment for a particular patient, and antibiotic susceptibility testing systems efficiently allow researchers to achieve it within a significantly short timeline.

With FDA approving a considerable number of antibiotic and microbial susceptibility testing equipment, especially in the recent past, FMI forecasts an impressive installed base for antibiotic susceptibility testing systems in coming years. Advanced technology enabled antibiotic susceptibility testing equipment allows early diagnosis that in turn improves chances of developing targeted therapy earlier. One such recent advancement enjoying visibly growing traction in market includes oCelloScope. This antibiotic susceptibility testing equipment by BioSense Solutions is an optical susceptibility screening system with the capability to deliver real-time, time-lapse imaging of multiple microbial combinations, simultaneously.

Recently, Thermo Fisher Scientific, Inc. and Becton, Dickinson and Company received FDA approvals for their new launches in antibiotic susceptibility testing space. Moreover, FDA passed an approval to a susceptibility testing device by bioMérieux that has an expanded capability to identify a particular pathogen.

Research in Screening of High Pathogen Concentration Samples to Propel Demand for AST

The process of spotting a specific set of genes responsible for antibiotic resistance is highly complicated when it comes to handling the complexities associated with samples that have high concentration of pathogens. Some of the highly desirable antibiotic susceptibility testing systems that allow direct-from-sample pathogen identification through high pathogen concentration samples, are thus likely to gain high traction in coming years.

Growing research efforts in the recognition of the presence of a specific set of antibiotic resistant genes can direct efforts for identification and selection of narrow-spectrum antibiotics, which remains among the most prominent factors pushing installed base of such antibiotic susceptibility testing equipment.

A few recent launches in this segment include

  • Genmark Diagnostics
  • ePLEX Blood Culture ID Panel
  • Biomerieux’s BioFire FilmArray
  • Luminex Corp.’s Verigene Bloodstream Infection Panel.

The report also sheds light on the increasing role of Ecommerce in the market by boosting the availability of antibiotic susceptibility testing systems. Offering improved access to susceptibility testing devices by industry’s leading brands, online retail operators have been attracting prominent vendors in the global antibiotic susceptibility testing market. A number of vendors dealing in antibiotic susceptibility testing equipment are opting for devices that are available online owing to the significantly reduced costs and additional discounts on price.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-8574

Additional Questions Answered

Some of the additional questions addressed in this report on the antibiotic susceptibility testing market-

  • What is the revenue potential of the antibiotic susceptibility testing market across regions of North America and Europe?
  • Who are the key competitors and what are their portfolios in the antibiotic susceptibility testing market?
  • What are the major challenges influencing the growth of the antibiotic susceptibility testing market?
  • How intervention from regulatory authorities is shaping the antibiotic susceptibility testing market growth?

Key Segment

Based on product type

  • instruments
    • automated broth microdilution systems
    • manual broth microdilution systems
    • semi-automated broth microdilution systems
  • software & services
    • image & analysis software
    • installation services
  • kits & reagents

Based on applications

  • sepsis
  • respiratory infections
  • gastrointestinal infections
  • meningitis & encephalitis
  • endocarditis
  • others

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-8574

Based on end user

  • diagnostic laboratories
  • hospitals
  • research laboratories

Based on regions

  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Cellulite Treatment Market to Reach US$ 2,100 Million, Globally, by 2027 at 8.1% CAGR: FMI

Cellulite is a health condition which is more prevalent in women. With the growing health related complexities witnessed in women, there’s also a growth in rate of people suffering from cellulite. A new research report by Future Market Insights revolves around examining the current scenario of global cellulite treatment market as well as forecast for its upcoming years. This comprehensive research report is titled ‘Cellulite Treatment Market: Global Industry Analysis 2013 – 2017 and Opportunity Assessment 2018 – 2028’.

Hard Cellulite Predicted to Hold an Attractive Market Share in the Near Future

One major driver behind the growth of cellulite treatment market is the increasing number of obese population. There are also increased number of cases for fat deposition. The people who are comparatively overweight mostly face this problem, in turn triggering the demand for cellulite treatment. These cases have helped people grow aware about cosmetic surgeries and has also broadened the scope of these surgeries in market. There’s a significant rise in aesthetic procedures taking place worldwide. Especially in Brazil, where there were around 5,500 cosmetic surgeons performing the second highest number of aesthetic procedures after the U.S. Around 1,450,020 minimally invasive and non-surgical procedures were performed in Brazil in 2016. Among different types of cellulite, hard cellulite is expected to register a growth rate of around 7.8% during 2018-2028, which is higher than other cellulite types.

To remain ‘ahead’ of your competitors, request for a sample

North America Slated for Strongest Projections in the Global Cellulite Treatment Market

Among the major regional divisions made for the research conducted on global cellulite treatment market, North America shows the strongest prospects with an expected market value of over US$ 2,100 Mn by the end of 2028, growing at an impressive CAGR of 8.1% during the forecast period. The growth is helped by North America’s moderate economy and healthcare market. Also, in the U.S., a large base of population, especially youngsters, suffer from fat deposition related disorders. The region is also ahead of other regions due to its developed economy and advanced facilities. The cellulite treatment involves advanced techniques which are also costly for people to afford. This makes the market more prominent in developed regions like North America.

Global Cellulite Treatment Market: Competitive Landscape

The research report has a detailed scenario of competition going on in the global cellulite treatment market. It includes a SWOT analysis of big companies that are vigorously involved providing cellulite treatments to people.

  • Merz Pharma GmbH & Co.
  • KGaA,
  • Cynosure, Inc. (Sub. Hologic Inc.),
  • Tanceuticals,
  • LLC.,
  • Inceler Medikal Co. Ltd.,
  • Cymedics,
  • Nubway,
  • Zimmer Aesthetics,
  • Syneron Medical Inc

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-3560

Market Taxonomy

Treatment Procedure

  • Non-Invasive
  • Minimally Invasive
  • Topical Treatment

Cellulite

  • Soft Cellulite
  • Hard Cellulite
  • Edematous Cellulite

End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialized Dermatology Clinics

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-3560

Region

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia-Pacific excluding Japan
  • China
  • Japan
  • Middle East & Africa

Exosome Diagnostic and Therapeutics Market is projected to expand at a high CAGR of 23.1% during the period of assessment

Future Market Insights in its recent research report titled “Exosome Diagnostic and Therapeutics Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)” covers several factors that are influencing the robust growth of the global market. As per this research report, the global exosome diagnostic and therapeutic market is projected to expand at a high CAGR of 23.1% during the period of assessment. The exhaustive research publication includes key trends, opportunities, threats, growth drivers and challenges that impact the global exosome diagnostic and therapeutics market. Detailed pricing analysis of different exosome diagnostic and therapeutics across key regions is also discussed in the research study. The segmental analysis across North America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Latin America, Japan and Middle East and Africa (MEA) is carried out which is used to track the future projections for a period of ten years, pertaining to value, of the global exosome diagnostic and therapeutics market.

To remain ‘ahead’ of your competitors, request for a sample

Global Market for Exosome Diagnostic and Therapeutics: Underlying Forces Influencing Growth

The growth of global market for exosome diagnostics and therapeutics is influenced by several factors. Increasing need for screening and diagnosis of chronic diseases coupled with high therapeutic potential of exosomes are fuelling the adoption of exosome diagnostics and therapeutics. Moreover, introduction of explicit systems for analysis of proteins specific to exosomes, increasing research and development activities supported by favourable government policies across various regions and increasing popularity of exosome over CTC and ctDNA are expected to trigger the growth of the global market for exosome diagnostic and therapeutics market in the years to follow. On the contrary, lack of standardization and validation requirements for isolation of exosomes is expected to pose hindrances to the growth of the global market. Other factors negatively impacting the market’s growth include heavy investments in research and development and insufficient insurance coverage of costly cancer diagnostic tests.

Segmentation Highlights of the Global Exosome Diagnostic and Therapeutics Market

The global exosome diagnostic and therapeutics market is segmented on the basis of product type, application, end user and region.

In the region category, North America is estimated to be the largest with a high market lucrativeness. This region is expected to grow at a significant CAGR during the forecast period to touch a large market estimation by end of the assessment year, thus leading the global market. Moreover, Asia Pacific excluding Japan (APEJ) is the fastest growing region and is the second largest in terms of adoption and use of exosome diagnostics and therapeutics. APEJ is filled with high growth opportunities and is being targeted by several giants in this sector, such as Thermo Fisher Scientific.

By product type, reagents and kits are gaining high traction owing to increasing use in exosome diagnostics and therapeutics. The reagents and kits segment dominated the market in 2017 and is anticipated to continue with the trend in the coming years. This segment is also expected to expand at a high growth rate during the forecast period. The reagents and kits segment is expected to register a high CAGR of 28.2% throughout the period of forecast. The software segment is the second fastest growing segment spurring the growth of the global market.

In the application category, diagnostic segment is the largest as compared to therapeutics segment and is estimated to touch a value of over US$ 90 Mn by the end of the year of assessment, growing at a significant pace. Therapeutics segment is projected to expand at a CAGR of 29.0% throughout the period of assessment.

With respect to end user, the use of exosome diagnostic and therapeutics is largely observed in diagnostic centres. The diagnostic centres segment is expected to surpass other end user segments with a high market share and growth rate in the coming years.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-6379

Forecast Analysis of the Global Exosome Diagnostic and Therapeutics Market

According to the research report, the global market for exosome diagnostic and therapeutics is expected to grow at a high CAGR to reach an estimate of over US$ 150 Mn by the end of the year of assessment from a value of about US$ 19 Mn in 2017.

Competitive Landscape Shaping the Global Exosome Diagnostic and Therapeutics Market

Manufacturers of exosome diagnostic and therapeutics are focusing to raise capital required for launch of new products or research and development expenses through venture financing. Key companies such as

  • Thermo Fisher Scientific Inc.
  • NanoSomix Inc.
  • NX PHARMAGEN
  • Capricor Therapeutics Inc.
  • Exosome Diagnostics Inc.
  • Exiqon A/S (Aethlon Medical Inc.).
  • System Biosciences Inc.
  • Aegle Therapeutics AMS Biotechnology (Europe) Limited
  • Miltenyi Biotec.

Market segmentation

By Product Type

    • Instrument
  • Software
  • Reagents and Kits

By Application

  • Diagnostics
  • Therapeutics

By End User

  • Hospitals
  • Cancer Institutes
  • Diagnostic Centres
  • Others

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-6379

By Region

  • North America
  • Latin America
  • Eastern Europe
  • Western Europe
  • Asia Pacific excluding Japan
  • Japan
  • Middle East and Africa